Mode
Text Size
Log in / Sign up
N/A N=100 Randomized Prevention

SmokefreeSGM, A Text-based Smoking Cessation Feasibility Trial for Sexual and Gender Minority Groups

Smoking Cessation

Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Feasibility as Assessed by Number of Participants Recruited for the Study — 100 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
SmokefreeSGM (Behavioral); SmokefreeTXT (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
The University of Texas Health Science Center, Houston
Primary completion
Jul 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Feasibility as Assessed by Number of Participants Recruited for the Study
100
PRIMARY
Feasibility as Assessed by Number of Participants That Completed Month 1 Visit
35; 34
PRIMARY
Feasibility as Assessed by Number of Participants That Completed Month 3 Visit
22; 20
PRIMARY
Feasibility as Assessed by Number of Participants That Completed Month 6 Visit
19; 16
PRIMARY
Acceptability as Assessed by Number of Participants Who Completed Qualitative Interviews
16; 9
SECONDARY
Number of Participants That Quit Smoking
3; 7
SECONDARY
Number of Participants That Quit Smoking
3; 7
SECONDARY
Number of Participants That Quit Smoking
3; 7

Summary

The purpose of this study is to test the feasibility and acceptability of Smokefree Sexual and Gender Minority (SGM), an SGM-tailored version of the SmokefreeTXT text messaging program

Eligibility Criteria

Inclusion Criteria

  • Self-identify as an LGBTQ+ individual
  • Currently live in the United States
  • Have smoked at least 100 cigarettes in their lifetime, smoke every day, and smoke greater than or equal to 5 cigarettes a day
  • Are willing to quit smoking in the next 15 days
  • Have a cell phone number with an unlimited short message service (SMS) plan
  • Have a positive cotinine saliva test to indicate their smoking status

Exclusion Criteria

  • Have a prepaid cell phone plan (pay-as-you-go plan)
  • Have a cell phone number that does not work and/or is registered to someone else
  • Have inadequate equipment/devices (i.e., webcam, speakers, mic) for participating in telehealth sessions via Microsoft Teams, Webex, or Zoom AND cannot meet in-person
  • Pregnant or breastfeeding persons (nicotine patches are not generally recommended to this groups since nicotine can affect fetal and neonatal brain development)
  • Contraindication for nicotine patches. Absolute contraindications include: severe eczema or serious skin conditions, allergy to nicotine patches, pregnancy, breastfeeding, heart attack in the past 2 months, ongoing angina, peptic ulcer disease, arrhythmia, or uncontrolled blood pressure. Potential contraindications include: stroke in the past 6 months, insulin therapy, and a current diagnosis of liver, kidney, or heart disease. Study participants reporting a potential contraindication will require approval from their primary care provider and/or other treating physician (e.g., psychiatrist) to use nicotine patches. If the request is denied or not returned in 2 weeks, potential study participants will be excluded from the study.
  • Current use of tobacco cessation medications
  • Enrollment in another smoking cessation study
  • Non-English speakers
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05645354). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search